A Phase 3 study to assess the efficacy and safety of JTZ-951 in ESA naive anemic patients with chronic kidney disease receiving hemodialysis <anemia correction / maintenance study> (SYMPHONY HD-naive)

Japan Tobacco Inc.0 个研究点目标入组 34 人开始时间: 2017年9月5日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Japan Tobacco Inc.
入组人数: 34

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

SYMPHONY HD-naive confirmed the effect of increases in Hb when JTZ-951 was administered at the initial dose of 4 mg once daily for 4 week. JTZ-951 was confirmed to be safe when administered for a total of up to 24 weeks.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•* ESA naive patients
•* Hemoglobin level of => 8.0 g/dL and < 10.0 g/d

排除标准

•Patients with poorly controlled hypertension
•Patients with congestive heart failure or unstable angina
•Patients with malignancy

研究者

发起方

Japan Tobacco Inc.

相似试验

已完成

3 期

Phase 3 Comparative Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis (SYMPHONY ND)Anemia with CKD

JPRN-jRCT2080223814Japan Tobacco Inc.216

已完成

3 期

Phase 3 Comparative Study of JTZ-951in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis (SYMPHONY HD)

JPRN-jRCT2080223881Japan Tobacco Inc.173

已完成

2 期

ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction / Maintenance Study>Anemia with CKD

JPRN-jRCT2080222839Japan Tobacco Inc.71

已完成

2 期

ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Anemia Correction / Switch / Maintenance Study>Anemia with CKD

JPRN-jRCT2080222829Japan Tobacco Inc.201

已完成

3 期

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated UlcersPeptic Ulcer

NCT00450658Amgen627